

IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1-3 (cancelled).

4-10 (withdrawn).

11 (cancelled).

12-20 (withdrawn).

21 (cancelled).

22-42 (withdrawn).

43-46 (cancelled).

47-53 (withdrawn).

54 (cancelled).

55-70 (withdrawn).

71 (cancelled).

72-85 (withdrawn).

86-87 (cancelled).

88-106 (withdrawn).

107-108 (cancelled).

109 (withdrawn).

110 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an

June 17, 2004

antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is lung cancer.

111 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is colorectal cancer.

112 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is breast cancer.

113 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is prostate cancer.

114 (currently amended). ~~The method of claim 1~~ A method for treating a

June 17, 2004

neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is bladder cancer.

115 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is ovary cancer.

116 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is cervical cancer.

117 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and

June 17, 2004

topotecan and a combination thereof, wherein the neoplasia disorder is gastrointestinal cancer.

118 (currently amended). ~~The method of claim 1-~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is head and neck cancer.

119 (currently amended). ~~The method of claim 44-~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is lung cancer.

120 (currently amended). ~~The method of claim 44-~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is colorectal cancer.

121 (currently amended). ~~The method of claim 44-~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method

June 17, 2004

comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is breast cancer.

122 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is prostate cancer.

123 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is bladder cancer.

124 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is ovary

June 17, 2004

cancer.

125 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is cervical cancer.

126 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is gastrointestinal cancer.

127 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is head and neck cancer.

128 (currently amended). ~~The method of claim 107 wherein~~ A method for treating a neoplasia disorder of the lung in a mammal in need of such treatment, which method comprises administering to said mammal a

June 17, 2004

therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ irinotecan.

129 (currently amended). ~~The method of claim 108 wherein~~ A method for treating a neoplasia disorder of the lung in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ irinotecan.

130 (currently amended). ~~The method of claim 107 wherein~~ A method for treating a neoplasia disorder of the lung in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ topotecan.

131 (currently amended). ~~The method of claim 108 wherein~~ A method for treating a neoplasia disorder of the lung in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ topotecan.

132 (currently amended). ~~The combination of claim 87 wherein~~ A combination comprising the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ irinotecan.

133 (currently amended). ~~The combination of claim 87 wherein~~ A

Serial No. 09/857,995

6794F-000037/US/01 (3167/5Z/US)

Amendment after final action under 37 CFR §1.116 (Amendment D)

June 17, 2004

combination comprising the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ topotecan.